Amphetamine neurotoxicity: Accomplishments and remaining challenges

Neuroscience and Biobehavioral Reviews

Volumn 27, Issue 8, 2004, Pages 821-826

  McCann, Una D ^a   Ricaurte, George A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dopamine; Drug abuse; MDMA; Methamphetamine; Monoamines; Serotonin

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMPHETAMINE; DOPAMINE; DOPAMINE RECEPTOR; METHAMPHETAMINE; SEROTONIN RECEPTOR;

CONFERENCE PAPER; DEGENERATIVE DISEASE; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG ABUSE; HISTORY; HUMAN; NERVE CELL DEGENERATION; NEUROBIOLOGY; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; TEMPERATURE DEPENDENCE;

EID: 1042266417     PISSN: 01497634     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2003.11.003     Document Type: Conference Paper

References (70)

1. Ricaurte G.A., McCann U.D. Neuropathology of cocaine abuse. Curr Opin Psychiatry. 12:(3):1999;277-280.
2. Rothman S.M., Olney J.W. Excitotoxicity and the NMDA receptor - still lethal after eight years. Trends Neurosci. 18:(2):1995;57-58.
3. Seiden L.S., Fischman M.W., Schuster C.R. Long-term methamphetamine induced changes in brain catecholamines in tolerant rhesus monkeys. Drug Alcohol Depend. 1:(3):1976;215-219.
4. Kogan F.J., Nichols W.K., Gibb J.W. Influence of methamphetamine on nigral and striatal tyrosine hydroxylase activity and on striatal dopamine levels. Eur J Pharmacol. 36:(2):1976;363-371.
5. Hotchkiss A.J., Gibb J.W. Long-term effects of multiple doses of methamphetamine on tryptophan hydroxylase and tyrosine hydroxylase activity in rat brain. J Pharmacol Exp Ther. 214:1980;257-262.
6. Ricaurte G.A., Schuster C.R., Seiden L.S. Long-term effects of repeated methylamphetamine administration on dopamine and serotonin neurons in the rat brain: a regional study. Brain Res. 193:(1):1980;153-163.
7. Gibb J.W., Hanson G.R., Johnson M. Neurochemical mechanisms of toxicity. Cho A., Segal D. Amphetamine and its analogs: neuropsychopharmacol, toxicology and abuse. 1994;269-289 Academic Press, New York.
8. Seiden L.S., Ricaurte G.A. Neurotoxicity of methamphetamine and related drugs. Meltzer H.Y. Psychopharmacology - a generation of progress. 1987;359-366 Raven Press, New York.
9. Lew R., Malberg J.E., Ricaurte G.A., Seiden L.S. Evidence for and mechanism of action of neurotoxicity of amphetamine related compounds. Kostrzewa R.M. Highly selective neurotoxins: basic and clinical applications. 1997;235-268 Humana Press, Totowa.
10. Frey K., Kilbourn M., Robinson T. Reduced striatal vesicular monoamine transporters after neurotoxic but not after behaviorally-sensitizing doses of methamphetamine. Eur J Pharmacol. 334:(2/3):1997;273-279.
11. Villemagne V., Yuan J., Wong D.F., Dannals R.F., Hatzidimitriou G., Mathews W.B., Ravert H.T., Musachio J., Mc Cann U.D., Ricqurte G.A. Brain dopamine neurotoxicity in baboons treated with doses of methamphetamine comparable to those recreationally abused by humans: evidence from [11C]WIN-35,428 positron emission tomography studies and direct in vitro determinations. J Neurosci. 18:(1):1998;419-427.
12. Hogan K.A., Staal R.G.W., Sonsalla P.K. Analysis of VMAT2 binding after methamphetamine or MPTP treatment: disparity between homogenates and vesicle preparations. J Neurochem. 74:(5):2000;2217-2220.
13. Ellison G., Eison M.S., Huberman H.S., Daniel F. Long-term changes in dopaminergic innervation of caudate nucleus after continuous amphetamine administration. Science. 201:1978;276-278.
14. Molliver M.E., Berger U.V., Mamounas L.A., Molliver D.C., O'Hearn E.G., Wilson M.A. Neurotoxicity of MDMA and related compounds: anatomic studies. Ann NY Acad Sci. 600:1990;640-664.
15. Axt K.J., Molliver M.E. Immunocytochemical evidence for methamphetamine-induced serotonergic axon loss in the rat brain. Synapse. 9:1991;302-313.
16. Ricaurte G.A., Guillery R.W., Seiden L.S., Schuster C.R., Moore R.Y. Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain. Brain Res. 235:1982;93-103.
17. Woolverton W.L., Ricaurte G.A., Forno L.S., Seiden L.S. Long-term effects of chronic methamphetamine administration in rhesus monkeys. Brain Res. 486:1989;73-78.
18. Sonsalla P.K., Jochnowitz N.D., Zeevalk G.D., Oostveen J.A., Hall E.D. Treatment of mice with methamphetamine produces cell loss in the substantia nigra. Brain Res. 38:(1):1996;172-175.
19. Hirata H., Cadet J.L. p53-Knockout mice are protected against the long-term effects of methamphetamine on dopaminergic terminals and cell bodies. J Neurochem. 69:1997;780-790.
20. Ricaurte G.A., Seiden L.S., Schuster C.R. Further evidence that amphetamines produce long-lasting dopamine neurochemical deficits by destroying dopamine nerve fibers. Brain Res. 303:1984;359-364.
21. Ryan L.J., Linder J.C., Martone M.E., Groves P.M. Histological and ultrastructural evidence that D-amphetamine causes degeneration in neostriatum and frontal cortex of rats. Brain Res. 518:1990;67-77.
22. O'Callaghan J.P., Miller D. Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J Pharmacol Exp Ther. 270:1994;741.
23. Fuller R.W. Persistent effects of amphetamine, p-chloroamphetamine, and related compounds on central dopamine and serotonin neurons in rodents. Psychopharmacol Bull. 21:(3):1985;528-532.
24. Commins D.L., Vosmer G., Virus R.M., Woolverton W.L., Schuster C.R., Seiden L.S. Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain. J Pharmacol Exp Ther. 241:(1):1987;338-345.
25. Steranka L.R., Sanders-Bush E. Long-term effects of continuous exposure to p-chloroamphetamine on central serotonergic mechanisms in mice. Biochem Pharmacol. 27:(16):1978;2033-2037.
26. Melega W.P., Raleigh M.J., Stout D.B., Lacan G., Huang S.C. Recovery of striatal dopamine function after acute amphetamine- and methamphetamine-induced neurotoxicity in the vervet monkey. Brain Res. 766:(1/2):1997;113-120.
27. Finnegan K.T., Ricaurte G.A., Ritchie L.D., Irwin I., Peroutka S.J., Langston J.W. Orally administered MDMA causes a long-term depletion of serotonin in rat brain. Brain Res. 447:1988;141-144.
28. Kleven M.S., Woolverton W.L., Seiden L.S. Evidence that both intragastric and subcutaneous administration of methylenedioxymethylamphetamine (MDMA) produce serotonin neurotoxicity in rhesus monkeys. Brain Res. 488:(1/2):1989;121-125.
29. Ricaurte G.A., DeLanney L.E., Irwin I., Langston J.W. Toxic effects of MDMA on central serotonergic neurons in the primate: importance of route and frequency of drug administration. Brain Res. 446:1988;165-168.
30. Ali S.F., Newport G.D., Scallet A.C., Binienda Z., Ferguson S.A., Bailey J.R., Paule M.G. Jr, Slikker W. Jr. Oral administration of 3,4- methylenedioxymethamphetamine (MDMA) produces selective serotonergic depletion in the nonhuman primate. Neurotoxicol Teratol. 15:(2):1993;91-96.
31. Slikker W. Jr, Ali S.F., Scallet A.C., Frith C.H., Newport G.D., Bailey J.R. Neurochemical and neurohistological alterations in the rat and monkey produced by orally administered methylenedioxymethamphetamine (MDMA). Toxicol Appl Pharmacol. 94:(3):1988;448-457.
32. Fuller R.W., Hemrick-Luecke S. Long-lasting depletion of striatal dopamine by a single injection of amphetamine in iprindole-treated rats. Science. 209:(4453):1990;395-397.
33. Peat M.A., Warren P.F., Gibb J.W. Effects of a single dose of methamphetamine and iprindole on the serotonergic and dopaminergic system of the rat brain. J Pharmacol Exp Ther. 225:(1):1983;126-131.
34. Sonsalla P.K., Nicklas W.J., Heikkila R.E. Role for excitatory amino acids in meth-amphetamine-induced nigrostriatal dopaminergic toxicity. Science. 243:1989;398-400.
35. Marek G.J., Vosmer G., Seiden L.S. The effects of monoamine uptake inhibitors and methamphetamine on neostriatal 6-hydroxydopamine (6-OHDA) formation, short-term monoamine depletions and locomotor activity in the rat. Brain Res. 516:(1):1990;1-7.
36. Fukumura M., Cappon G., Cunfeng P., Broening H., Vorhees C. A single dose model of methamphetamine-induced neurotoxicity in rats: effects on neostriatal monoamines and glial fibrillary acidic protein. Brain Res. 806:1998;1-7.
37. Fumagalli F., Gainetdinov R.R., Valenzano K.J., Caron M.G. Role of dopamine transporter in methamphetamine-induced neurotoxicity: evidence from mice lacking the transporter. J Neurosci. 18:1998;4861.
38. Abekawa T., Ohmori T., Koyama T. Tolerance to the neurotoxic effect of methamphetamine in rats behaviorally sensitized to methamphetamine or amphetamine. Brain Res. 767:(1):1997;34-44.
39. Stephans S., Yamamoto B. Methamphetamine pretreatment and the vulnerability of the striatum to methamphetamine neurotoxicity. Neuroscience. 72:(3):1996;593-600.
40. Segal D.S., Kuczenski R. An escalating dose 'binge' model of amphetamine psychosis: behavioral and neurochemical characteristics. J Neurosci. 17:(7):1997;2551-2566.
41. Schmidt C.J. Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. J Pharmacol Exp Ther. 240:1987;1-7.
42. Fuller R.W., Hemrick-Luecke S.K. Further studies on the long-term depletion of striatal dopamine in iprindole-treated rats by amphetamine. Neuropharmacology. 21:(5):1982;433-438.
43. 11C]WIN-35,428. J Neurosci. 18:1998;8417-8422.
44. Volkow N.D., Chang L., Wang G.J., Fowler J.S., Leonido-Yee M., Franceschi D., Sedler M.J., Gatley S.J., Hitzemann R., Ding Y.S., Logan J., Wong C., Miller E.N. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry. 158:(3):2001;377-382.
45. Sekine Y., Iyo M., Ouchi Y., Matsunaga T., Tsukada H., Okada H., Yoshikawa E., Futatsubashi M., Takei N., Mori N. Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am J Psychiatry. 158:(8):2001;1206-1214.
46. Ricaurte G.A., Fuller R.W., Perry K.W., Seiden L.S., Schuster C.R. Fluoxetine ncreases long-lasting neostriatal dopamine depletion after administration of D-methamphetamine and D-amphetamine. Neuropharmacology. 22:1983;1165-1169.
47. Marek G.J., Vosmer G., Seiden L.S. Dopamine uptake inhibitors block long-term neurotoxic effects of methamphetamine upon dopaminergic neurons. Brain Res. 513:(2):1990;274-279.
48. Bowyer J.F., Tank A.W., Newport G.D., Slikker W. Jr, Ali S.F., Holson R.R. The influence of environmental temperature on the transient effects of methamphetamine on dopamine levels and dopamine release in rat striatum. J Pharmacol Exp Ther. 260:1992;817-824.
49. Bowyer J.F., Gough B., Slikker W. Jr, Lipe G.W., Newport G.D., Holson R.R. Effects of a cold environment or age on methamphetamine-induced dopamine release in the caudate putamen of female rats. Pharmacol Biochem Behav. 44:1993;87-98.
50. Bowyer J.F., Davies D.L., Schmued L., Broening H.W., Newport G.D., Slikker W. Jr, Holson R.R. Further studies of the role of hyperthermia in methamphetamine neurotoxicity. J Pharmacol Exp Ther. 268:1994;1571.
51. Ali S.F., Newport G.D., Holson R.R., Slikker W. Jr, Bowyer J.F. Low environmental temperatures or pharmacologic agents that produce hypothermia decrease methamphetamine neurotoxicity in mice. Brain Res. 658:(1/2):1994;33-38.
52. Ali S.F., Newport G.D., Slikker W. Jr. Methamphetamine-induced dopaminergic toxicity in mice. Role of environmental temperature and pharmacological agents. Ann NY Acad Sci. 801:1996;187-198.
53. Farfel G.M., Seiden L.S. Role of hypothermia in the mechanism of protection against serotonergic toxicity. I. Experiments using 3,4-methylenedioxymethamphetamine, dizocilpine, CGS19755 and NBQX. J Pharmacol Exp Ther. 272:1995;860-867.
54. Farfel G.M., Seiden L.S. Role of hypothermia in the mechanism of protection against serotonergic toxicity. II. Experiments with methamphetamine, p-chloroamphetamine, fenfluramine, dizocilpine and dextromethorphan. J Pharmacol Exp Ther. 272:1995;868-875.
55. Albers D.S., Sonsalla P.K. Methamphetamine-induced hyperthermia and dopaminergic neurotoxicity in mice: pharmacological profile of protective and nonprotective agents. J Pharmacol Exp Ther. 275:(3):1995;1104-1114.
56. Yuan J., Callahan B.T., McCann U.D., Ricaurte G.A. Evidence against an essential role of endogenous brain dopamine in methamphetamine-induced dopaminergic neurotoxicity. J Neurochem. 77:(5):2001;1338-1347.
57. Callahan B., Yuan J., Stover G., Hatzidimitriou G., Ricaurte G.A. Effects of 2-deoxy-D-glucose on methamphetamine-induced dopamine and serotonin neurotoxicity. J Neurochem. 70:(1):1998;190-197.
58. Callahan B.T., Ricaurte G.A. Effect of 7-nitroindazole on body temperature and methamphetamine-induced dopamine toxicity. NeuroReport. 9:1998;2691-2695.
59. Schmidt C.J., Ritter J.K., Sonsalla P.K., Hanson G.R., Gibb J.W. Role of dopamine in the neurotoxic effects of methamphetamine. J Pharmacol Exp Ther. 233:(3):1985;539-544.
60. Cubells J.F., Rayport S., Rajindron G., Sulzer D. Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular stress. J Neurosci. 14:1994;2260-2771.
61. Lotharius J., O'Malley K.L. Role of mitochondrial dysfunction and dopamine-dependent oxidative stress in amphetamine-induced toxicity. Ann Neurol. 49:(1):2001;79-89.
62. Yamamoto B.K., Zhu W. The effects of methamphetamine on the production of free radicals and oxidative stress. J Pharmacol Exp Ther. 287:(1):1998;107-114.
63. Shankaran M., Yamamoto B.K., Gudelsky G.A. Ascorbic acid prevents 3,4-methylenedioxymethamphetamine (MDMA)-induced hydroxyl radical formation and the behavioral and neurochemical consequences of the depletion of brain 5-HT. Synapse. 40:(1):2001;55-64.
64. Kita T., Takahashi M., Kubo K., Wagner G.C., Nakashima T. Hydroxyl radical formation following methamphetamine administration to rats. Pharmacol Toxicol. 85:(3):1999;133-137.
65. Wan F.J., Lin H.C., Lin Y.S., Tseng C.J. Intra-striatal infusion of D-amphetamine induces hydroxyl radical formation: inhibition by MK-801 pretreatment. Neuropharmacology. 39:(3):2000;419-426.
66. Volkow N.D., Chang L., Wang G.J., Fowler J.S., Franceschi D., Sedler M., Gatley S.J., Miller E., Hitzemann R., Ding Y.S., Logan J. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neurosci. 21:(23):2001;9414-9418.
67. Ricaurte G.A., Sabol K.E., Seiden L.S. Functional consequences of toxic amphetamine analog exposure. Cho A., Segal D. Amphetamine and its analogs: neuropsychopharmacology, toxicology and abuse. 1994;297-309 Academic Press, New York.
68. Wallace T.L., Gudelsky G.A., Vorhees C.V. Methamphetamine-induced neurotoxicity alters locomotor activity, stereotypic behavior, and stimulated dopamine release in the rat. J Neurosci. 19:(20):1999;9141-9148.
69. McCann U.D., Szabo Z., Scheffel U., Dannals R.F., Ricaurte G.A. Positron emission tomographic evidence of toxic effect of MDMA ('Ecstasy') on brain serotonin neurons in human beings. Lancet. 352:1998;1433-1437.
70. Buchert R., Thomasius R., Nebeling B., Petersen K., Obrocki J., Jenicke L., Wilke F., Wartberg L., Zapletalova P., Clausen M. Long-term effects of 'ecstasy' use on serotonin transporters of the brain investigated by PET. J Nucl Med. 44:(3):2003;375-384.